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A B S T R A C T
Background: Recent study demonstrated that HLA-B*1502 was a common risk allele in aromatic
antiepileptic drugs (AEDs) induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han
Chinese. However, the association of AEDs-induced mild maculopapular eruption (MPE) with HLA-
B*1502 remains unclear until recently. In the present study, we conducted a pilot study to detect a
possible association of oxcarbazepine (OXC)-induced MPE with HLA-B*1502 allele in Chinese Han
population.
Methods: We enrolled 90 subjects involving 9 patients with OXC-induced MPE and two groups of
controls, 9 OXC-tolerant and 72 normal controls. High-resolution HLA genotyping was performed by
speciﬁc kit. The results of HLA genotyping are expressed as positive or negative for HLA-B*1502 allele.
Differences in genotype frequencies between groups were assessed by the Fisher’s exact test.
Results: Four cases were detected as positive for HLA-B*1502 amongst 9 patients. However, only 1
subject was positive amongst 9 tolerant controls, and 6 subjects were positive amongst 72 normal
controls. The difference in HLA-B*1502 allele frequencies between the MPE group and normal controls
was statistically signiﬁcant (OR: 8.8; 95% CI: 1.853–41.790; P = 0.011). In addition, we also observed an
increased frequency of HLA-B*1502 allele in patients (44.44%) comparedwith tolerant controls (11.11%),
although it failed to reach statistical signiﬁcance (P = 0.294).
Conclusions: Our ﬁndings indicate that HLA-B*1502 allele may contribute to the genetic susceptibility to
OXC-induced MPE in Chinese Han population. In order to safer AEDs use, we recommend that HLA-
B*1502 allele should be tested for patients with OXC-induced MPE before changing to other AEDs, and
AEDs with similar chemical structure should be avoided in individuals who test positive for HLA-B*1502
allele. It should be pointed out that, however, our results may well be just by chance owing to the small
sample size and should be further conﬁrmed in future studies.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Antiepileptic drugs (AEDs) are one of the most common causes
of cutaneous adverse drug reactions (cADRs). cADRs are mostly
unpredictable and potentially life-threatening during antiepileptic
therapy. The clinical manifestation of cADRs varies from mild
maculopapular eruption (MPE), with increasing severity, to life-
threatening severe cutaneous reaction (SCR), which includes
Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis
(TEN) and drug hypersensitivity syndrome (HSS).1 The overall
incidence of various forms of AEDs-induced cADRs is approxi-
mately 10%.2 MPE is more common than HSS or SJS/TEN with an* Corresponding author. Tel.: +86 28 85423038; fax: +86 28 85423550.
E-mail address: zhoudong66@yahoo.de (D. Zhou).
1 These authors contributed equally to this work.
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.11.014overall incidence rate of 2.8% amongst all AEDs users.3 cADRs is a
large burden on healthcare system and antiepileptic therapy is
often limited by different cADRs. Therefore, preventing these
cADRs is an important goal for improving patient safety.
Recent pharmacogenetic studies have uncovered a strong
association between carbamazepine (CBZ)-induced SJS/TEN and
human leucocyte antigen HLA-B*1502 allele in Asian popula-
tions.4–9 These data indicate that HLA-B*1502 allele may be a
genetic marker for CBZ-induced SJS/TEN in Asians other than Han
Chinese. Identiﬁcation of genetic factors contributing to the
development of AEDs-induced SCR offers the possibility of
avoiding these high-risk drugs in genetically susceptible individu-
als. Therefore, the United States Food and Drug Administration (US
FDA) updated the CBZ label to include genetic information and
recommended genetic screening for HLA-B*1502 allele before
starting CBZ therapy in Asians.10 These genetic advances arose
increasing scientiﬁc interest amongst researchers to examine thevier Ltd. All rights reserved.
Table 1
Allele frequencies of HLA-B*1502 amongst all subjects.
Groups N Allele (%)
HLA-B*1502 Non HLA-B*1502
OXC-induced MPEa 9 4 (44.4%) 5 (55.6%)
OXC-tolerant control 9 1 (11.1%) 8 (88.9%)
Normal controlb 72 6 (8.3%) 66 (91.7%)
a OXC-induced MPE compared with OXC-tolerant control: odds ratio =6.4, 95%
CI: 0.5471–74.891, P=0.294.
b OXC-induced MPE compared with normal control: odds ratio =8.8, 95% CI:
1.853–41.790, P=0.011.
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lamotrigine and OXC. Further study demonstrated that aromatic
AEDs-induced SJS/TEN share a common risk allele HLA-B*1502.9
Here, an important issue has been arose whether AEDs-induced
MPE is associated with HLA-B*1502 allele. Previous pharmacoge-
netic studies focused primarily on the AEDs-induced SCR.
Regretfully, AEDs-induced MPE has attracted less attentions,
although it may also be important to reveal the genetic link of
AEDs-induced cADRs. Recent study suggested that CBZ-induced
MPEwas lack of associationwithHLA-B*1502 allele.5 However, the
association between other AEDs-induced MPE and HLA-B*1502
allele has not been examined in different ethnic populations. In the
present study, we conducted a pilot study to detect a possible
association of OXC-induced MPE with HLA-B*1502 allele in
Chinese Han population from mainland China.
2. Patients and methods
The study protocol was approved by the Ethics committee of
Sichuan University and written informed consent was obtained
from all participants. We conducted a case–control association
study involving 9 patients with OXC-induced MPE and two groups
of controls, 9 OXC-tolerant and 72 unrelated healthy controls. All
patients with OXC-induced MPE were consecutively recruited
from our epilepsy center. In addition, we enrolled 9 subjects who
had been on OXC for more than 3 months without any cADRs as
tolerant controls. All cases and controls were ethnic Han Chinese
indigenous to mainland China. MPE is characterized by cutaneous
itchy and erythematous macules and papules after administration
of antiepileptic medicines, and spontaneously resolve within 1–2
weeks after withdrawing the causative drugs.11 Genomic DNAwas
extracted from peripheral blood lymphocytes using standard
phenol–chloroform procedures. High-resolution HLA genotyping
was performed by polymerase chain reaction sequencing-based
typing (PCR-SBT) assay using speciﬁc kit (Bioassay Laboratory of
CapitalBio Corporation, Beijing, China). The results of HLA
genotyping are denoted as positive or negative for HLA-B*1502
allele. Fisher’s exact test was used to analyze the possible
association between OXC-induced MPE and HLA-B*1502 allele.
A two-tailed P value of <0.05 was considered to be statistically
signiﬁcant.
3. Results
In this study, we successfully performed high-resolution HLA
genotyping for 90 subjects. Four cases were demonstrated as
positive for HLA-B*1502 allele amongst 9 patients with OXC-
induced MPE. By comparison, only 1 subject was positive for HLA-
B*1502 allele amongst 9 OXC-tolerant controls, and 6 subjects
were positive amongst 72 normal controls (shown in Table 1). The
difference in HLA-B*1502 frequency between the MPE group and
normal controls was statistically signiﬁcant (OR: 8.8; 95% CI:Table 2
Characteristics of patients with oxcarbazepine-induced MPE.
Patient ID Sex Age (years) Race Disease
1 F 14 Han Chinese Epilepsy
2 M 22 Han Chinese Epilepsy
3 M 8 Han Chinese Epilepsy
4 M 16 Han Chinese PKC
5 F 17 Han Chinese Epilepsy
6 M 16 Han Chinese Epilepsy
7 F 18 Han Chinese Epilepsy
8 F 29 Han Chinese Epilepsy
9 F 16 Han Chinese Epilepsy
PKC: paroxysmal kinesigenic choreoathetosis; MPE: maculopapular eruption.1.853–41.790; P = 0.011). In addition, we also found that patients
with OXC-inducedMPE (44.44%) had an increased frequency of the
HLA-B*1502 allele compared with OXC-tolerant controls (11.11%),
although it failed to reach statistical signiﬁcance (P = 0.294).
Clinical characteristics of the 9 patients with OXC-inducedMPE
are summarized in Table 2. The onset of symptoms for all patients
with MPE occurred within the ﬁrst 40 days of OXC exposure.
Amongst these patients, including four males and ﬁve females, the
mean dosage of OXC was 366.7 mg/day and latency to MPE from
drug exposure was 17.3 days. For the four HLA-B*1502 allele
carriers, the mean dosage of OXC was 300 mg/day and the latency
to MPE was 14.5 days. All patients with OXC-induced MPE were
complete recovery after withdrawing the causative drugs. By
comparison, the tolerant controls received OXC with a mean
dosage of 533.3 mg/days and duration of more than 3 months. It
can be seen that the tolerant controls administrated higher doses
of OXC than the MPE groups and no adverse drug reactions were
observed.
4. Discussion
A new anticonvulsant, OXC, was introduced into Chinese
market for antiepileptic therapy before 7 years. OXC, a 10-keto
analogue of CBZ, is considered to be much safer than CBZ owing to
its different metabolic pathway.12 OXC is almost completely
metabolized through reduction and conjugation to yield an active
monohydroxy derivative (MHD), which is glucuronidated and
excreted in the urine. In contrast, the oxidation of CBZ to 10,11-
epoxide is regarded as the most common cause of side effects.13
The estimated relative risk of OXC-SJS was 30–40-fold lower than
that of CBZ-SJS in Han Chinese of Taiwan.14 To date, only ﬁve
patients with OXC-induced SJS/TEN have been reported, and four
of them were HLA-B*1502 positive.9,14,15 Recently, OXC is
increasingly used as ﬁrst-line drug in the treatment of partial
epilepsy with or without secondary generalization in mainland
China due to the better safety than CBZ. Although OXC and CBZ
share the similar chemical structure, signiﬁcant differences still
exist in all aspects between the two drugs.13 Therefore, it is
necessary to further examine the possible association of OXC-Dose of OXC (mg) Latency to MPE (days) HLA-B*1502 allele
300 14 Positive
600 16 Negative
300 10 Negative
300 2 Negative
300 40 Negative
150 21 Positive
600 30 Negative
300 5 Positive
450 18 Positive
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show signiﬁcant association between CBZ-induced MPE and HLA-
B*1502 allele.5
The present study demonstrated an association between HLA-
B*1502 allele and OXC-induced MPE in Han Chinese. The risk of
OXC-inducedMPEwas signiﬁcantly higher in the patients with the
HLA-B*1502 allele, with an OR of 8.8 (95% CI: 1.853–41.790,
P = 0.011). Furthermore, we also observed a higher frequency of
HLA-B*1502 allele in patients with OXC-inducedMPE compared to
OXC-tolerant controls. Therefore, we speculate that HLA-B*1502
allele may increase the genetic risk for OXC-induced MPE in
Chinese Han population. Our results are different from those of the
previous study, suggesting that there was no signiﬁcant associa-
tion of CBZ-induced MPE with HLA-B*1502 allele.5 These discrep-
ant results could be mainly due to different chemical structure
between OXC and CBZ. In addition, other HLA alleles or genetic
markers/environmental factors may also contribute to the
development of AEDs-induced MPE, except for HLA-B*1502 allele.
Previous study have found that CBZ-induced MPE was associated
with some single nucleotide polymorphisms (SNPs, including
rs1264511 and rs1059510) in the HLA-E region and a nearby allele,
HLA-A*3101.5
Patients who develop cADRs on one drug may develop another
episode of cADRs when changed to other drugs with similar
chemical structures.16 This crossreactivity has been observed in
patients receiving antiepilepticmedicines. Furthermore, cADRs are
most commonly encountered amongst patients treated with
aromatic AEDs.17,18 Previous clinical studies indicated that
aromatic AEDs, including CBZ, OXC, Phenobarbital (PB), phenytoin
(PHT) and lamotrigine (LTG), have a 20–30% chance of cross-
reacting, and 25–70% of OXC-hypersensitive patients react to
CBZ.19–21 Recent retrospective observation in Chinese population
showed that 66.7% of OXC-hypersensitive patients react to CBZ,
25% of OXC-hypersensitive patients react to LTG and 25% of OXC-
hypersensitive patients react to PHT.22 Although these cross-
reactivities of cADRs are primarily observed as mild skin rashes,
such as MPE.11 However, it remains unclear whether patients with
OXC-induced MPE will develop another episode of MPE or SCR
when changed to other AEDs. Therefore, caution is necessary when
prescribing the alternative AEDs for patients with OXC-induced
MPE. Given the high frequency of HLA-B*1502 allele in patients
with OXC-inducedMPE and the crossreactivities of cADRs amongst
various AEDs, we recommend that HLA-B*1502 allele should be
tested for patients with OXC-induced MPE before changing to
other AEDs, and that other aromatic AEDs should be avoided in
individuals who develop OXC-induced MPE and simultaneously
test positive for HLA-B*1502 allele.
In this exploratory study, we speciﬁcally typed the HLA-B gene
to detect the presence of HLA-B*1502 allele using a commercial kit.
This kit is based on the sequencing assay and thus has good
speciﬁcity. To our knowledge, this is the ﬁrst report that show an
association between AEDs-induced MPE and HLA-B*1502 allele in
Chinese Han population. Therefore, our results may have a positive
effect on the genetic study of AEDs-induced cADRs and safe AEDs
use in future, although it may be not sufﬁcient to inﬂuence the
present clinical practice. However, it should be noted that this is asmall sample study, which limited the statistical power to detect a
signiﬁcant difference in HLA-B*1502 allele frequency between
cases and controls. Therefore, our results may be just a chance
ﬁnding and need to be further conﬁrmed in larger studies.
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